The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes

• David J. Dowling ,

  Contributed equally to this work with: David J. Dowling, Zhen Tan

  Affiliations Department of Medicine, Division of Infectious Diseases, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Zhen Tan ,

  Contributed equally to this work with: David J. Dowling, Zhen Tan

  Affiliations Department of Medicine, Division of Infectious Diseases, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America, Division of Pediatrics, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  ⨯
• Zofia M. Prokopowicz,

  Affiliations Department of Medicine, Division of Infectious Diseases, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Christine D. Palmer,

  Affiliations Department of Medicine, Division of Infectious Diseases, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Maura-Ann H. Matthews,

  Affiliation VentiRx Pharmaceuticals, Inc., Seattle, Washington, United States of America

  ⨯
• Gregory N. Dietsch,

  Affiliation VentiRx Pharmaceuticals, Inc., Seattle, Washington, United States of America

  ⨯
• Robert M. Hershberg,

  Affiliation VentiRx Pharmaceuticals, Inc., Seattle, Washington, United States of America

  ⨯
• Ofer Levy

  * E-mail: ofer.levy@childrens.harvard.edu

  Affiliations Department of Medicine, Division of Infectious Diseases, Boston Children’s Hospital, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯